SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Feb 14, 2022

Keywords

ClinConnect Summary

The SOLOMON trial is a study aimed at understanding how non-cancerous brain tumors, such as meningiomas and schwannomas, grow over time. Since 2001, patients at Seoul National University Hospital who have been diagnosed with these types of tumors have had follow-up MRI scans to monitor their condition. The goal is to gather important information about the natural growth patterns of these tumors, which can help doctors make better decisions about treatment in the future.

To be eligible for this study, participants must be at least 18 years old and have been diagnosed with a non-cancerous brain tumor that doesn’t require immediate treatment. They should be feeling well when they first visit the hospital and must have had at least two MRI scans spaced three months apart. The study is currently recruiting participants of all genders. If you choose to participate, you can expect to have regular MRI scans to track your tumor's growth, with the added benefit of contributing to valuable research that may help others in the future.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria for retrospective cohort
• • Patients with radiologically diagnosed brain neoplasm of CNS WHO grade 2 or less since 1998
• • Asymptomatic at first visit to the hospital
• • Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit
• • Patients who have had two or more MRs at least 3 months apart
• • No previous radiotherapy or radiosurgery for the brain lesion
• • 18 years old or more
• • Inclusion Criteria for prospective cohort
• • Patients with newly diagnosed brain neoplasm of CNS WHO grade 2 or less
• • Asymptomatic at first visit to the hospital
• • Patients who, based on the up-to-date knowledge, did not necessarily require immediate treatment at the first hospital visit and who are going to take follow-up MR exams
• • No previous radiotherapy or radiosurgery for the brain lesion
• • 18 years old or more
• • Patients who agree to participate by written consent
• • Exclusion Criteria
• • Patients who lost follow-up before the second MR exam
• • Patients requiring immediate treatment due to worsening of symptoms within 3 months of the first MR exam
• • Patients suspected to have other than a neoplasm at follow-up MR exams